Portolano Cavallo

Life Sciences

Blog

Portolano Cavallo Life Sciences Blog
25 Feb
Procurement of biosimilar medicines in public tenders: Regulatory framework and recent caselaw
The procurement of biosimilars intended for the entities of the National Health Service, while generally regulated by the Public Procurement Code, is subject to special rules due to the unique characteristics of these products compared to chemically derived medicines.
25 Feb
Anti-counterfeiting of medicines: The new provisions of the Decree implementing delegated Regulation on falsified medicines
On February 6, 2025 the new Legislative Decree 10/2025 implementing the Delegated Regulation (EU) 2016/161 on the anti-counterfeiting of medicinal products was approved.
25 Feb
Supplementing rules to the Public Procurement Code: The new Decree and its impact on tenders and contracts
The new Legislative Decree 209/2024 introduces complementary and corrective provisions to the Italian Public Procurement Code with the aim of simplifying the current legislation and solving the problems that have arisen in the application of the new provisions of the Code, as also requested by the European Union.
24 Feb
Budget law 2025: News for the healthcare sector
Annual budget laws bring numerous changes that also affect the healthcare sector. Let's look at the main novelties.
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the Life Sciences-Healthcare industry.
...
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and Venture Capital transactions.

Close
October 6, 2023
CBD products: the Administrative Court suspended until October 24 the recent Decree of the Italian Ministry of Health listing cannabidiol for oral use among narcotic drugs, due to the lack o...
October 4, 2023
The Guidelines for regulating contractual relations between universities and research institutes and private sponsors were adopted by the relevant Italian Ministries following the amendment ...
September 21, 2023
CBS products: from September 20th, compositions for oral administration of cannabidiol obtained from Cannabis sativa extracts shall be considered as narcotic drugs in Italy, as they have bee...
July 27, 2023
Payback on medical devices: Italian government announces extension of payment deadline to October 30, 2023
July 21, 2023
On July 21, 2023, the Italian Ministry of Health published new guidelines on health advertising of self-medication drugs (OTC) and non-prescription drugs (SOP), including advertising on new ...
Search by...
Search
Follow us on
Follow us on